Background
ALBERT, LUTZ
Edited by: Salman Sadullah Usmani, Albert Einstein College of Medicine, United StatesReviewed by: Larry Ellingsworth, Novavax, Inc., United States; Elizabeth De Gaspari, Adolfo Lutz Institute, Brazil†These authors have contributed equally to this work and share first authorshipUpdated vaccine strategies are needed to protect against new SARS-CoV-2 variants with increased immune escape. Here, information on the safety and immunogenicity of an inactivated Omicron-adapted vaccine is presented, as compared with CoronaVac.